Physician profile
Doris Gokool
NPI 1053543504
$6,573.85
in general payments reported to CMS, 2019-2025
33 companies · $1,562 in 2025
The $1,562 reported for 2025 was more than what 92% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $835 · 2022: $1,449 · 2023: $1,176 · 2024: $1,552 · 2025: $1,562.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,002 · Education: $288.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,001.71 |
| Education | $287.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $981.44 | 2021-2025 | Acthar, Terlivaz |
| Astrazeneca Pharmaceuticals LP | $805.30 | 2021-2025 | Farxiga, Airsupra, Lokelma |
| Otsuka America Pharmaceutical, INC. | $626.86 | 2021-2025 | Jynarque, Voyxact |
| Vifor Pharma, INC. | $399.64 | 2021-2025 | Veltassa |
| Bayer Healthcare Pharmaceuticals INC. | $341.17 | 2021-2025 | |
| Amgen INC. | $339.97 | 2022-2025 | Tavneos |
| Calliditas Therapeutics US INC. | $310.36 | 2022-2025 | Tarpeyo |
| Opko Pharmaceuticals, LLC | $305.39 | 2021-2025 | Rayaldee |
| Travere Therapeutics, INC. | $251.81 | 2023-2025 | Filspari |
| Ardelyx, INC. | $231.39 | 2023-2025 | Ibsrela |
| Aurinia Pharma U.S., INC. | $206.11 | 2022-2025 | Lupkynis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $196.82 | 2023-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $169.59 | 2024-2025 | |
| Horizon Therapeutics Plc | $169.58 | 2021-2023 | Krystexxa |
| Fresenius USA Marketing, INC. | $159.88 | 2022-2024 | Korsuva, Velphoro |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $144.33 | 2022-2024 | Renal - Pd |
| Renalytix Ai, INC. | $131.22 | 2024-2025 | Kidneyintelx Blood Collection Convenience Kit |
| Glaxosmithkline, LLC. | $122.19 | 2022-2025 | Benlysta, Shingrix, Arexvy |
| Ultragenyx Pharmaceutical INC. | $85.44 | 2021-2022 | |
| Kyowa Kirin, INC. | $81.51 | 2023-2024 | Crysvita |
| Lilly USA, LLC | $74.82 | 2024-2025 | Jardiance |
| Scpharmaceuticals INC. | $59.93 | 2025 | |
| Alexion Pharmaceuticals, INC. | $56.21 | 2022-2023 | |
| Vantive US Healthcare LLC | $55.29 | 2025 | Renal - Pd |
| Apellis Pharmaceuticals, INC. | $49.42 | 2025 | Empaveli |
| Ani Pharmaceuticals, INC. | $49.26 | 2025 | Purified Cortrophin Gel |
| Alnylam Pharmaceuticals INC. | $45.93 | 2021-2024 | Givlaari |
| Corcept Therapeutics | $41.08 | 2025 | Korlym |
| Ascendis Pharma Endocrinology INC | $22.21 | 2025 | Yorvipath |
| Novo Nordisk INC | $16.84 | 2023 | Rybelsus, Ozempic |
| Azurity Pharmaceuticals, INC. | $16.71 | 2025 | |
| Akebia Therapeutics INC | $13.74 | 2021 | |
| Arbor Pharmaceuticals, INC. | $12.41 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Doris Gokool listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.